



7-6-04

IFW

PHA 4231.1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Ellen G. McMahon, et al. Art Unit 1614
Serial No. 10/803,818
Filed March 18, 2004
Confirmation No. 7016
For COMBINATION OF AN ALDOSTERONE RECEPTOR ANTAGONIST AND AN
ENDOTHELIN RECEPTOR ANTAGONIST AND/OR ENDOTHELIN CONVERTING
ENZYME INHIBITOR

July 2, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. In accordance with the OG notice of August 5, 2003 partially waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied. Applicants submit herewith copies of the foreign patent documents/literature references.

Respectfully submitted,

Anthony R. Kinney, Reg. No. 44,834
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

ARK/crm/leb
*Enclosures

Express Mail Label No. EV 237015556 US
Mail Stop Amendment

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 				Complete if Known	
				Application Number	10/803,818
				Filing Date	March 18, 2004
				Confirmation Number	7016
				First Named Inventor	McMahon, et al.
				Group Art Unit	1614
Examiner Name	To Be Assigned				
Sheet	1	of	3	Attorney Docket No.	PHA 4231.1

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	1	4,559,332		Grob, et al.	12-17-1985		
	2	5,594,021		Chan, et al.	01-14-1997		
	3	5,883,254		Göhring	03-16-1999		
	4	6,043,265		Murugesan, et al.	03-28-2000		
	5	6,162,927		Winn, et al.	12-19-2000		
	6	6,638,937	B2	Murugesan, et al.	10-28-2003		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	7	WO	00/27380	A2	Perez, et al.	05-18-2000	
	8	WO	00/51642	A1	Alexander, et al.	09-08-2000	
	9	WO	01/44239	A3	Murugesan, et al.	06-21-2001	
	10	WO	01/95892	A1	Williams, et al.	12-20-2001	
	11	WO	01/95893	A1	Williams, et al.	12-20-2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,818
				Filing Date	March 18, 2004
				Confirmation Number	7016
				First Named Inventor	McMahon, et al.
				Group Art Unit	1614
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket No.	PHA 4231.1

	12	WO	02/09683	A2	Rocha, et al.	02-07-2002	
	13	WO	02/09759	A2	Rocha, et al.	02-07-2002	
	14	WO	02/09760	A2	Alexander, et al.	02-07-2002	
	15	WO	02/09761	A2	Schuh	02-07-2002	
	16	WO	96/40255	A2	Egan, et al.	12-19-1996	
	17	WO	96/40257	A1	Alexander, et al.	12-19-1996	
	18	WO	99/16466	A2	Letvin, et al.	04-08-1999	

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	19	B.Pitt, et al., The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure, The New England Journal of Medicine, September 2, 1999, pgs. 709-717, Vol. 341, No. 10	
	20	H. Krum, New and Emerging Pharmacologic Strategies in the Management of Chronic Heart Failure, Clin. Cardiol., 2000, pgs. 724-730, Vol. 23	
	21	A. Rudolph, et al., Emerging Therapies for Heart Failure, Expert Opinion Emerging Drugs, 2002, pgs. 247-258, Vol. 7(2)	
	22	Endothelin-Receptor Blocker Shown Beneficial in Pulmonary Hypertension, Reuters Medical News, Lancet, 2001	
	23	D. Giannessi, et al., The Role of Endothelins and Their Receptors in Heart Failure, Pharmacological Research, 2001, pgs. 111-126, Vol. 43, No. 2	
	24	S. Boyd, et al., Discovery of a Series of Pyrrolidine-Based Endothelin Receptor Antagonists with Enhanced ET _A Receptor Selectivity, Bioorganic & Medicinal Chemistry, 1999, pgs. 991-1002, Vol. 7	
	25	D. Morgan, American Society for Clinical Pharmacology and Therapeutics 99th Annual Meeting, IDrugs, 1998, pgs. 1-8, Vol. 1(1)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/803,818
				Filing Date	March 18, 2004
				Confirmation Number	7016
				First Named Inventor	McMahon, et al.
				Group Art Unit	1614
				Examiner Name	To Be Assigned
Sheet	3	of	3	Attorney Docket No.	PHA 4231.1

	26	P. Cowburn, et al., Selective or Non-Selective Endothelin Receptor Antagonists for Chronic Heart Failure: What Do We Know So Far?, J. Clin. Basic Cardiol., 1999, pgs. 41-44, Vol. 2	
	27	A. Ergul, Endothelin-1 and Endothelin Receptor Antagonists as Potential Cardiovascular Therapeutic Agents, Pharmacotherapy, 2002, pgs. 54-65, Vol. 22(1)	
	28	É. Fontaine, et al., Effects of Phosphoramidon, BQ 788, and BQ 123 on Coronary and Cardiac Dysfunctions of the Failing Hamster Heart, Journal of Cardiovascular Pharmacology, July 1998, pgs. 12-20, Vol. 32(1)	
	29	D. Feldman, et al., Attenuation of Puromycin Aminonucleoside-Induced Glomerular Lesions in Rats by CGS 26303, a Dual Neutral Endopeptidase/Endothelin-Converting Enzyme Inhibitor, Journal of Cardiovascular Pharmacology, 2000, pgs. S342-S345, Vol. 36	
	30	A. Yasuyuki, et al., TMC-66, A New Endothelin Converting Enzyme Inhibitor, The Journal of Antibiotics, July 1999, pgs. 607-612, Vol. 52, No. 7	
	31	Y. Matsumura, et al., Protective Effect of SM-19712, a Novel and Potent Endothelin Converting Enzyme Inhibitor, on Ischemic Acute Renal Failure in Rats, Jpn. J. Pharmacol., 2000, pgs. 16-24, Vol. 84	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.